Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy.

Pablo García-PavíaMartha GroganParag KaleJohn L BerkMathew S MaurerIsabel ConceiçãoMarcelo Di CarliScott D SolomonChongshu ChenElena YurenevaJohn VestJulian D Gillmore

Published in: European journal of heart failure (2024)

Vutrisiran demonstrated evidence of potential benefit on cardiac manifestations in patients with ATTRv amyloidosis with polyneuropathy, with an acceptable safety profile.

Keyphrases

left ventricular
multiple myeloma
risk assessment